Founded out of the Harvard University Quantum Computing Lab in 2017, Zapata Quantum develops hardware-agnostic quantum software tools aimed at translating theoretical quantum advantage into practical utility. The company has worked across industries including pharmaceuticals, finance, materials science, defense, and cryptography, and has supported Fortune 500 companies and public sector organizations. A recent collaboration with Dana-Farber Cancer Institute, University of Toronto, and Insilico Medicine produced a quantum-enabled drug discovery study targeting KRAS mutations that was recognized among the top scientific papers of 2025 by Nature Biotechnology. Zapata plans to expand its platform and grow scientific, engineering, product, and commercial teams while deepening its AI-driven development approach. It is also pursuing formal algorithm validation partnerships such as with the University of Maryland. Financially, Zapata recently completed an oversubscribed $15 million financing as the final stage of a year-long restructuring, positioning the company to accelerate growth and move customers from experimentation to production-ready quantum solutions.

Total raised

$79M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2026